Q-omics provides the consensus-scored NSFL1C profile across patient tissues and cancer cell-line models. NSFL1C expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NSFL1C is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NSFL1C RNA expression shows 17,707 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where NSFL1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NSFL1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NSFL1C survival associations across molecular data types. NSFL1C RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NSFL1C RNA expression–survival associations across cancer types. High NSFL1C expression shows unfavorable associations in MESO, ACC, HNSC, LIHC, COAD and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for NSFL1C RNA expression.
This table summarizes NSFL1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NSFL1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NSFL1C shows higher tumor expression in HNSC, KIRC, LIHC, STAD, LUSC and BLCA. The HNSC box plot shows higher NSFL1C RNA expression in tumor versus normal tissue (log2 FC = +0.663, t-test p < 0.001).
This table shows molecular features associated with NSFL1C in patient tissues and cancer cell lines. In patient samples, NSFL1C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NSFL1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
